Impact of Nuedexta on Bulbar Physiology and Function in ALS


The purpose of this research is to determine if Nuedexta, an FDA approved and routinely prescribed medication, improves speech and swallowing functions in people with ALS.


If you agree to participate, you will be asked to attend 2 evaluations 30-days apart and undergo a swallowing x-ray study, cough testing, speech testing, and a tongue pressure exam.


  • 18-90 years old
  • Diagnosis of probable-definite ALS (El-Escorial Criterion); ALSFRS-R Bulbar subscale score <10
  • Bamboo oral reading speaking rate <140 words per minute
  • No allergies to barium sulfate

For additional study information, please contact Kelby Magennis:


18 to 65
65 and over



Monetary compensation


Can be done from home



ALS, ALS - resources, Amyotrophic lateral sclerosis, Neurology

Principal Investigator

Emily K. Plowman, PhD, CCC-SLP



Contact Information


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams